Recent Management of Patients with Advanced Epidermal Growth Factor Receptor Mutation Non-small Cell Lung Cancer: Role of Afatinib and Lesson Learned for Developing Countries

Keyphrases

• Developing Countries 100%
• Lessons Learned 100%
• EGFR mutation 100%
• Patient Management 100%
• Non-small Cell Lung Cancer (NSCLC) 100%
• Afatinib 100%
• National Health Insurance 60%
• Erlotinib 60%
• Gefitinib 60%
• Metastatic Non-small Cell Lung Cancer 40%
• Second-generation Tyrosine Kinase Inhibitors 40%
• Indonesia 20%
• High Mortality Rate 20%
• High Incidence 20%
• Recent Advances 20%
• Intolerance 20%
• Adverse Effects 20%
• Incidence Rate 20%
• Lung Cancer 20%
• Conventional Treatment 20%
• National Hospital 20%
• Morbidity Rate 20%
• Tyrosine Kinase Inhibitor 20%
• Disease Control 20%
• High Morbidity 20%
• Chemoresistance 20%
• Long Progression-free Survival 20%
• Free Charge 20%
• Cytotoxic Chemotherapy 20%
• First-generation TKI 20%
• Tyrosine Kinase Receptor 20%

Pharmacology, Toxicology and Pharmaceutical Science

• Non Small Cell Lung Cancer 100%
• Epidermal Growth Factor Receptor 100%
• Afatinib 100%
• Erlotinib 60%
• Protein Tyrosine Kinase Inhibitor 60%
• Gefitinib 60%
• Disease 40%
• Mortality Rate 20%
• Malignant Neoplasm 20%
• Adverse Event 20%
• Drug Resistance 20%
• Lung Cancer 20%
• Morbidity 20%
• Progression Free Survival 20%
• Cytotoxic Chemotherapy 20%
• Tyrosine Kinase Receptor 20%